UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.

1. Stay because you get equitable value from your firm.

The U.S. Department of Labor granted UBS a waiver the Swiss bank needs to continue managing U.S. retirement plans after a ...

John Tortorella's Philadelphia Flyers (19-20-6) are in Elmont on Thursday evening to take on Patrick Roy's New York Islanders ...

Tony Smith of Stonegate Investment Group discusses transitioning from UBS after 14 years and $4.4 billion in AUM to ...

The Federal Reserve is expected to cut rates further in 2025, paving the way for slightly lower borrowing costs for consumers ...

The infrastructure unit under Chow Tai Fook Enterprises said it will apply to list the new shares on the Hong Kong exchange.

Investing.com -- UBS downgraded Saint Gobain (EPA: SGOB) to Neutral from Buy in a note Thursday, citing limited upside ...

A group of investors being advised by Maverick Carter, Los Angeles Lakers star LeBron James’ business partner, is seeking to ...

UBS predicts that the Budgets focus on fiscal discipline may dampen market sentiment, particularly if FY26 capital ...

The Siegel-WisdomTree Model Portfolios are now available on the UBS Financial Services Inc. separately managed account ...

(Bloomberg Opinion) -- The big question for UBS Group AG shareholders is how badly its share buyback promises will be knocked ...